Curing CML with imatinib—a dream come true?
- 1 February 2011
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 8 (3), 127-128
- https://doi.org/10.1038/nrclinonc.2011.17
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Blood, 2010
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trialThe Lancet Oncology, 2010
- Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCRLeukemia, 2010
- Relapse and Late Mortality in 5-Year Survivors of Myeloablative Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia in First Chronic PhaseJournal of Clinical Oncology, 2010
- Significant Higher Rates of Undetectable Molecular Residual Disease and Molecular Responses with Pegylated Form of Interferon a2a in Combination with Imatinib (IM) for the Treatment of Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukaemia (CML) Patients (pts): Confirmatory Results at 18 Months of Part 1 of the Spirit Phase III Randomized Trial of the French CML Group (FI LMC).Blood, 2009
- Minimum viable population size: A meta-analysis of 30 years of published estimatesBiological Conservation, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 yearsBlood, 2006
- BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistanceBlood, 2006
- The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.1998